数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Karen N. Prange Director 56 未披露 未持股 2020-04-08
Regina E. Groves Director 61 19.75万美元 未持股 2020-04-08
Karen N. Prange Director 56 17.88万美元 未持股 2020-04-08
Mark A. Collar Director 67 19.25万美元 未持股 2020-04-08
Mark R. Lanning Director 65 20.00万美元 未持股 2020-04-08
Sven A. Wehrwein Director 69 20.25万美元 未持股 2020-04-08
B. Kristine Johnson Director 68 20.00万美元 未持股 2020-04-08
Michael H. Carrel President, Chief Executive Officer and Director 49 582.98万美元 未持股 2020-04-08
Robert S. White Director 58 19.75万美元 未持股 2020-04-08
Daniel P. Florin Director 55 17.88万美元 未持股 2020-04-08
Scott W. Drake Chairman of the Board and Director 52 23.00万美元 未持股 2020-04-08

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Justin J. Noznesky Senior Vice President, Marketing and Business Development 42 128.21万美元 未持股 2020-04-08
Salvatore Privitera Chief Technical Officer 53 129.00万美元 未持股 2020-04-08
Michael H. Carrel President, Chief Executive Officer and Director 49 582.98万美元 未持股 2020-04-08
M. Andrew Wade Chief Financial Officer 45 167.71万美元 未持股 2020-04-08
Douglas J. Seith Chief Operating Officer 54 206.74万美元 未持股 2020-04-08

董事简历

中英对照 |  中文 |  英文
Karen N. Prange
暂无中文简介

Karen N. Prange has served as one of our directors since December 2019. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein and a member of the Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she led the Urology and Pelvic Health business for Boston Scientific, Inc. and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. Ms. Prange serves on the boards of Cantel Medical Corp., Nevro Corp. and WSAudiology and is a strategic advisor of Nuvo Group Ltd. Ms. Prange earned her B.S. in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.
暂无中文简介
Karen N. Prange has served as one of our directors since December 2019. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein and a member of the Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she led the Urology and Pelvic Health business for Boston Scientific, Inc. and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. Ms. Prange serves on the boards of Cantel Medical Corp., Nevro Corp. and WSAudiology and is a strategic advisor of Nuvo Group Ltd. Ms. Prange earned her B.S. in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.
Regina E. Groves

Regina E.Groves自2017年3月起担任我们的董事之一。Groves女士目前担任Stimwave Technologies,Inc.(一家私人持有的医疗设备公司)的首席运营官和董事会成员。Groves女士于2015年9月至2019年3月担任医疗器械公司Reva Medical,Inc.的首席执行官,该公司专注于用于血管应用的生物可吸收聚合物技术的开发和商业化。在加入Reva Medical公司之前,Groves女士曾担任全球领先的医疗技术公司美敦力公司公司房颤解决方案、心律和心力衰竭部门的Vice President和总经理。在该职位上,她成功开发并执行了重新进入基于导管的AFIB消融市场的策略,并实现了在阵发性或间歇性AFIB消融中成为市场领导者的目标。此外,Groves女士成功地收购和整合了公司,完成了许多临床试验,并在美国和全球推出了新颖的产品。此前,她曾担任Medtronic公司的心脏节律疾病管理CRDM业务的质量和监管Vice President(2006年至2008年),此前曾担任Medtronic公司的Vice President兼患者管理CRDM总经理(2002年至2006年)。Groves女士拥有佛罗里达大学(University of Florida)的药学学士学位和哈佛大学工商管理研究生院(Harvard Graduate School of Business Administration)的工商管理硕士学位。


Regina E. Groves has served as one of our directors since March 2017. Ms. Groves currently serves as the Chief Operating Officer and a board member of Stimwave Technologies, Inc. a privately held medical device company. Ms. Groves was the Chief Executive Officer at REVA Medical, Inc., a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications from September 2015 to March 2019. Prior to joining REVA Medical, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, Inc., a leading global medical technology company. In this position, she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. Additionally, Ms. Groves successfully acquired and integrated companies, completed numerous clinical trials and launched novel products in the United States and worldwide. Prior to this, she was the Vice President of Quality and Regulatory for Medtronic’s Cardiac Rhythm Disease Management CRDM business from 2006 to 2008 and before that was Vice President and General Manager for Patient Management CRDM at Medtronic from 2002 to 2006. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration.
Regina E.Groves自2017年3月起担任我们的董事之一。Groves女士目前担任Stimwave Technologies,Inc.(一家私人持有的医疗设备公司)的首席运营官和董事会成员。Groves女士于2015年9月至2019年3月担任医疗器械公司Reva Medical,Inc.的首席执行官,该公司专注于用于血管应用的生物可吸收聚合物技术的开发和商业化。在加入Reva Medical公司之前,Groves女士曾担任全球领先的医疗技术公司美敦力公司公司房颤解决方案、心律和心力衰竭部门的Vice President和总经理。在该职位上,她成功开发并执行了重新进入基于导管的AFIB消融市场的策略,并实现了在阵发性或间歇性AFIB消融中成为市场领导者的目标。此外,Groves女士成功地收购和整合了公司,完成了许多临床试验,并在美国和全球推出了新颖的产品。此前,她曾担任Medtronic公司的心脏节律疾病管理CRDM业务的质量和监管Vice President(2006年至2008年),此前曾担任Medtronic公司的Vice President兼患者管理CRDM总经理(2002年至2006年)。Groves女士拥有佛罗里达大学(University of Florida)的药学学士学位和哈佛大学工商管理研究生院(Harvard Graduate School of Business Administration)的工商管理硕士学位。
Regina E. Groves has served as one of our directors since March 2017. Ms. Groves currently serves as the Chief Operating Officer and a board member of Stimwave Technologies, Inc. a privately held medical device company. Ms. Groves was the Chief Executive Officer at REVA Medical, Inc., a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications from September 2015 to March 2019. Prior to joining REVA Medical, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, Inc., a leading global medical technology company. In this position, she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. Additionally, Ms. Groves successfully acquired and integrated companies, completed numerous clinical trials and launched novel products in the United States and worldwide. Prior to this, she was the Vice President of Quality and Regulatory for Medtronic’s Cardiac Rhythm Disease Management CRDM business from 2006 to 2008 and before that was Vice President and General Manager for Patient Management CRDM at Medtronic from 2002 to 2006. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration.
Karen N. Prange

Karen N. Prange最近于2016年至2018年担任Henry Schein, Inc.(以下简称“Henry Schein”)全球动物健康、医疗和牙科集团执行副总裁副总裁兼首席执行官以及执行委员会成员。在这个职位上,她领导的公司在三个不同的业务部门创造了超过60亿美元的收入,将业务发展到所有业务部门都高于市场的水平。在加入Henry Schein之前,她是波士顿科学公司的高级副总裁兼泌尿外科和盆腔健康业务总裁,并曾在强生公司担任微血管内血管和Codman神经血管业务总经理。除了担任一般管理职务外,Prange女士在商业和业务方面也有丰富的经验,包括管理创新管道以及收购和整合公司。Prange女士目前在WS Audiology A/S董事会任职,还曾于2019年9月起担任医疗器械公司Nuvo Group战略顾问,于2020年3月起担任全球投资机构EQT集团产业顾问。Prange女士以优异成绩在佛罗里达大学获得工商管理理学学士学位,并在加州大学洛杉矶分校安德森商学院和史密斯学院完成了高管教育课程。


Karen N. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. ("Henry Schein") and a member of its Executive Committee from 2016 to 2018. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies. Ms. Prange currently serves on the board of WS Audiology A/S. She has also served as Strategic Advisor to Nuvo Group, Ltd. a medical device company, since September 2019 and Industrial Advisor to EQT Group, a global investment organization, since March 2020.Ms. Prange earned her Bachelor of Science in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.
Karen N. Prange最近于2016年至2018年担任Henry Schein, Inc.(以下简称“Henry Schein”)全球动物健康、医疗和牙科集团执行副总裁副总裁兼首席执行官以及执行委员会成员。在这个职位上,她领导的公司在三个不同的业务部门创造了超过60亿美元的收入,将业务发展到所有业务部门都高于市场的水平。在加入Henry Schein之前,她是波士顿科学公司的高级副总裁兼泌尿外科和盆腔健康业务总裁,并曾在强生公司担任微血管内血管和Codman神经血管业务总经理。除了担任一般管理职务外,Prange女士在商业和业务方面也有丰富的经验,包括管理创新管道以及收购和整合公司。Prange女士目前在WS Audiology A/S董事会任职,还曾于2019年9月起担任医疗器械公司Nuvo Group战略顾问,于2020年3月起担任全球投资机构EQT集团产业顾问。Prange女士以优异成绩在佛罗里达大学获得工商管理理学学士学位,并在加州大学洛杉矶分校安德森商学院和史密斯学院完成了高管教育课程。
Karen N. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. ("Henry Schein") and a member of its Executive Committee from 2016 to 2018. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies. Ms. Prange currently serves on the board of WS Audiology A/S. She has also served as Strategic Advisor to Nuvo Group, Ltd. a medical device company, since September 2019 and Industrial Advisor to EQT Group, a global investment organization, since March 2020.Ms. Prange earned her Bachelor of Science in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.
Mark A. Collar

Mark A. Collar,2008年2月以来,他一直担任我们的董事。他于2008年退任宝洁公司的职务,包括总裁,负责全球制药和个人健康的业务。他于1975年加入宝洁公司,担任销售代表,并依次担任广告、健康和个人护理、美容保健、新业务开发、制药和个人卫生保健产品一系列部门的职务,已逾32年。他现在拥有自己的投资和咨询业务,是 First Financial Bancorp(上市银行控股公司)的董事,也担任一些慈善,学术和经济开发组织的董事和顾问。他获得北伊利诺伊大学的学士学位。


Mark A. Collar has served as one of our directors since February 2008. Mr. Collar is the owner of Collar, Ltd., an investment and consulting business. Mr. Collar retired in 2008 as an officer within the Procter and Gamble Company where his roles included President of the Global Pharmaceuticals and Personal Health business. Mr. Collar joined Procter and Gamble in 1975 as a sales representative, then moved into advertising, and subsequently assumed roles of progressive responsibility within the Health and Personal Care, Beauty Care, New Business Development, Pharmaceuticals and Personal Health Care Products divisions over his 32-year career. Mr. Collar recently served as a director of First Financial Bancorp; Enable Injections, a privately-held start-up company focusing on high volume injection devices for biologic drugs; and as Chairman and Director of Marketing at TTRC, LLC Invisible Ink Tattoo Removers, a national tattoo removal chain. Mr. Collar also serves in director and advisory roles in several philanthropic, academic and economic development organizations. Mr. Collar received his B.S. from Northern Illinois University.
Mark A. Collar,2008年2月以来,他一直担任我们的董事。他于2008年退任宝洁公司的职务,包括总裁,负责全球制药和个人健康的业务。他于1975年加入宝洁公司,担任销售代表,并依次担任广告、健康和个人护理、美容保健、新业务开发、制药和个人卫生保健产品一系列部门的职务,已逾32年。他现在拥有自己的投资和咨询业务,是 First Financial Bancorp(上市银行控股公司)的董事,也担任一些慈善,学术和经济开发组织的董事和顾问。他获得北伊利诺伊大学的学士学位。
Mark A. Collar has served as one of our directors since February 2008. Mr. Collar is the owner of Collar, Ltd., an investment and consulting business. Mr. Collar retired in 2008 as an officer within the Procter and Gamble Company where his roles included President of the Global Pharmaceuticals and Personal Health business. Mr. Collar joined Procter and Gamble in 1975 as a sales representative, then moved into advertising, and subsequently assumed roles of progressive responsibility within the Health and Personal Care, Beauty Care, New Business Development, Pharmaceuticals and Personal Health Care Products divisions over his 32-year career. Mr. Collar recently served as a director of First Financial Bancorp; Enable Injections, a privately-held start-up company focusing on high volume injection devices for biologic drugs; and as Chairman and Director of Marketing at TTRC, LLC Invisible Ink Tattoo Removers, a national tattoo removal chain. Mr. Collar also serves in director and advisory roles in several philanthropic, academic and economic development organizations. Mr. Collar received his B.S. from Northern Illinois University.
Mark R. Lanning

Mark R. Lanning先生是一名注册会计师,也是一名全球特许管理会计师。Lanning先生自2006年2月以来一直打是我公司的董事会成员之一。他目前是弗里施餐厅(Frisch's Restaurants)的财务副总裁和首席财务官。在加盟弗里施餐厅之前,Lanning先生曾是希伦布兰德公司 (Hillenbrand, Inc.)公司、Hill-Rom公司和希伦布兰德工业公司(Hillenbrand Industries)的副总裁、投资者关系负责人兼财务总监。希伦布兰德工业公司是一家提供医疗设备、殡葬服务和材料处理的多元化公司。1988年,Lanning先生加盟了希伦布兰德公司,在这之前Lanning先生曾在安永威尼(Ernst & Whinney,现称“EY”)工作了12年,从事多项会计方面的职务。Lanning先生是一名注册会计师和全球特许管理会计师,目前是美国注册会计师协会(AICPA)的行业执行委员会成员。此外,他还是美国注册会计师协会理事会的成员之一,他曾是印第安娜注册会计师协会(Indiana CPA Society)的前任董事长以及董事会成员。Lanning先生获得了波尔州立大学(Ball State University)的会计学士学位。


Mark R. Lanning has served as one of our directors since February 2006. Mr. Lanning currently is a financial consultant and a principal of the Lanning CPA Group. Previously Mr. Lanning served as Vice President-Finance and Chief Financial Officer of Frisch’s Restaurants from 2011 to 2016. During his tenure with Frisch’s, Mr. Lanning led the process of transforming then publicly-traded Frisch’s to a privately-held company which included the strategic disposition of major operations. Prior to joining Frisch’s, Mr. Lanning served in various roles, including Vice President, Investor Relations Officer and Treasurer of publicly-traded Hillenbrand, Inc., Hill-Rom, Inc. and Hillenbrand Industries, diversified leaders in the healthcare equipment, funeral services, and material handling industries. Mr. Lanning also spent twelve years in increasing positions of responsibility with Ernst & Whinney now EY. Mr. Lanning, a Certified Public Accountant, is a past member of the Governing Council of the American Institute of CPAs (AICPA), is a past Chairman and Board member of the Indiana CPA Society and has served on the boards of several charitable and educational institutions over the years. Mr. Lanning received his B.S. in Accounting from Ball State University.
Mark R. Lanning先生是一名注册会计师,也是一名全球特许管理会计师。Lanning先生自2006年2月以来一直打是我公司的董事会成员之一。他目前是弗里施餐厅(Frisch's Restaurants)的财务副总裁和首席财务官。在加盟弗里施餐厅之前,Lanning先生曾是希伦布兰德公司 (Hillenbrand, Inc.)公司、Hill-Rom公司和希伦布兰德工业公司(Hillenbrand Industries)的副总裁、投资者关系负责人兼财务总监。希伦布兰德工业公司是一家提供医疗设备、殡葬服务和材料处理的多元化公司。1988年,Lanning先生加盟了希伦布兰德公司,在这之前Lanning先生曾在安永威尼(Ernst & Whinney,现称“EY”)工作了12年,从事多项会计方面的职务。Lanning先生是一名注册会计师和全球特许管理会计师,目前是美国注册会计师协会(AICPA)的行业执行委员会成员。此外,他还是美国注册会计师协会理事会的成员之一,他曾是印第安娜注册会计师协会(Indiana CPA Society)的前任董事长以及董事会成员。Lanning先生获得了波尔州立大学(Ball State University)的会计学士学位。
Mark R. Lanning has served as one of our directors since February 2006. Mr. Lanning currently is a financial consultant and a principal of the Lanning CPA Group. Previously Mr. Lanning served as Vice President-Finance and Chief Financial Officer of Frisch’s Restaurants from 2011 to 2016. During his tenure with Frisch’s, Mr. Lanning led the process of transforming then publicly-traded Frisch’s to a privately-held company which included the strategic disposition of major operations. Prior to joining Frisch’s, Mr. Lanning served in various roles, including Vice President, Investor Relations Officer and Treasurer of publicly-traded Hillenbrand, Inc., Hill-Rom, Inc. and Hillenbrand Industries, diversified leaders in the healthcare equipment, funeral services, and material handling industries. Mr. Lanning also spent twelve years in increasing positions of responsibility with Ernst & Whinney now EY. Mr. Lanning, a Certified Public Accountant, is a past member of the Governing Council of the American Institute of CPAs (AICPA), is a past Chairman and Board member of the Indiana CPA Society and has served on the boards of several charitable and educational institutions over the years. Mr. Lanning received his B.S. in Accounting from Ball State University.
Sven A. Wehrwein

Sven A. Wehrwein,2006年8月起,他担任董事。1999年起,他担任新兴公司的独立金融顾问。他曾担任35年多的投资银行家、首席财务官和不活动的注册会计师。他目前担任上市公司订制配件制造商Proto Labs, Inc.和供应链管理软件公司SPS Commerce的董事会成员。2007至2011年被戴尔公司(Dell Inc.) 收购,他担任Compellent Technologies, Inc.的董事会成员;1997至2011年被东芝医疗(Toshiba Medical)收购,担任Vital Images, Inc.的董事会成员;2004至2012年被Baxter International, Inc.收购,担任Synovis Life Technologies, Inc.的董事会成员;2006至2012年,担任Image Sensing Systems, Inc. 的董事会成员。


Sven A. Wehrwein has served as one of our directors since November 2016. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. During his 35-plus years in accounting and finance, Mr. Wehrwein has experience as a certified public accountant inactive, investment banker to emerging-growth companies, chief financial officer and audit committee chair. Mr. Wehrwein currently serves as the Chairman of the Board of Directors of Proto Labs, Inc., a custom prototype manufacturer, and as a member of the Board of Directors of SPS Commerce, Inc., a supply-chain management software company, both of which are publicly-traded companies. Mr. Wehrwein has also served on the boards of directors for a number of other medical device and high growth companies including tenures on the boards of Cogentix Medical, Inc., Compellent Technologies, Inc., Synovis Life Technologies, Inc. and Vital Images. Mr. Wehrwein holds a B.S. in Business from Loyola University of Chicago and an M.S. in Management from the Sloan School, MIT.
Sven A. Wehrwein,2006年8月起,他担任董事。1999年起,他担任新兴公司的独立金融顾问。他曾担任35年多的投资银行家、首席财务官和不活动的注册会计师。他目前担任上市公司订制配件制造商Proto Labs, Inc.和供应链管理软件公司SPS Commerce的董事会成员。2007至2011年被戴尔公司(Dell Inc.) 收购,他担任Compellent Technologies, Inc.的董事会成员;1997至2011年被东芝医疗(Toshiba Medical)收购,担任Vital Images, Inc.的董事会成员;2004至2012年被Baxter International, Inc.收购,担任Synovis Life Technologies, Inc.的董事会成员;2006至2012年,担任Image Sensing Systems, Inc. 的董事会成员。
Sven A. Wehrwein has served as one of our directors since November 2016. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. During his 35-plus years in accounting and finance, Mr. Wehrwein has experience as a certified public accountant inactive, investment banker to emerging-growth companies, chief financial officer and audit committee chair. Mr. Wehrwein currently serves as the Chairman of the Board of Directors of Proto Labs, Inc., a custom prototype manufacturer, and as a member of the Board of Directors of SPS Commerce, Inc., a supply-chain management software company, both of which are publicly-traded companies. Mr. Wehrwein has also served on the boards of directors for a number of other medical device and high growth companies including tenures on the boards of Cogentix Medical, Inc., Compellent Technologies, Inc., Synovis Life Technologies, Inc. and Vital Images. Mr. Wehrwein holds a B.S. in Business from Loyola University of Chicago and an M.S. in Management from the Sloan School, MIT.
B. Kristine Johnson

B. Kristine Johnson,2012年5月起在董事会任职。2000年起,她担任风险投资公司Affinity Capital Management的总裁,该公司向位于美国的私营医疗保健公司进行投资。1999年担任Affinity Capital Management的顾问前,她是Medtronic, Inc.的高级副总裁和首席行政官,以及Medtronic执行委员会成员。在Medtronic工作的17年中,她还担任其血管业务的总裁和总经理,以及快速性心律失常管理业务的总裁和总经理。她获有St. Olaf College学士学位。她现在领先的中级市场投资银行和资产管理公司Piper Jaffray Companies董事会任职,2012年起担任首席董事。她是St. Olaf College评议委员会主席,还在几家私营公司董事会任职。


B. Kristine Johnson has served as one of our directors since March 2017. Ms. Johnson is President of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States. She has held this position since 2000. Prior to joining Affinity Capital Management in 1999 Ms. Johnson was Senior Vice President and Chief Administrative Officer of Medtronic, Inc. During her seventeen years at Medtronic, she also served as President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business. She currently serves as a director for ClearPoint Neuro, formerly MRI Interventions. She also serves as the board chair of the University of Minnesota Foundation Investment Advisors, as well as serving on the boards of several private entities. She previously served on the Board of Directors of Piper Jaffray, a publicly-held middle market investment bank and asset management firm. Her previous public board experience also includes service on the Boards of Directors of Spectranetics Corporation, which was acquired by Philips, ADC Telecommunications, which was acquired by Tyco Electronics, and Pentair. Ms. Johnson received her B.A. from St. Olaf College.
B. Kristine Johnson,2012年5月起在董事会任职。2000年起,她担任风险投资公司Affinity Capital Management的总裁,该公司向位于美国的私营医疗保健公司进行投资。1999年担任Affinity Capital Management的顾问前,她是Medtronic, Inc.的高级副总裁和首席行政官,以及Medtronic执行委员会成员。在Medtronic工作的17年中,她还担任其血管业务的总裁和总经理,以及快速性心律失常管理业务的总裁和总经理。她获有St. Olaf College学士学位。她现在领先的中级市场投资银行和资产管理公司Piper Jaffray Companies董事会任职,2012年起担任首席董事。她是St. Olaf College评议委员会主席,还在几家私营公司董事会任职。
B. Kristine Johnson has served as one of our directors since March 2017. Ms. Johnson is President of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States. She has held this position since 2000. Prior to joining Affinity Capital Management in 1999 Ms. Johnson was Senior Vice President and Chief Administrative Officer of Medtronic, Inc. During her seventeen years at Medtronic, she also served as President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business. She currently serves as a director for ClearPoint Neuro, formerly MRI Interventions. She also serves as the board chair of the University of Minnesota Foundation Investment Advisors, as well as serving on the boards of several private entities. She previously served on the Board of Directors of Piper Jaffray, a publicly-held middle market investment bank and asset management firm. Her previous public board experience also includes service on the Boards of Directors of Spectranetics Corporation, which was acquired by Philips, ADC Telecommunications, which was acquired by Tyco Electronics, and Pentair. Ms. Johnson received her B.A. from St. Olaf College.
Michael H. Carrel

Michael H. Carrel,他担任主席,首席执行官和董事(2012年11月以来)。他担任Vital Images(上市医疗成像软件公司)的总裁兼首席执行官(从2008年到2012年)。他最初于2005年1月加入Vital Images,担任首席运营官和首席财务官。在Vital Images 任职期间,他领导公司成为保健和医疗软件行业的领导者。在他的领导下,公司的收入和利润增长,全球市场份额增加,遍布90多个国家,并股权融资筹集了1亿美元。此前,他担任Zamba集团(上市科技公司)的总裁兼首席执行官,以及NextNet Wireless(即插即用宽带无线接入系统的私人供应商,现在属于摩托罗拉公司)的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。


Michael H. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
Michael H. Carrel,他担任主席,首席执行官和董事(2012年11月以来)。他担任Vital Images(上市医疗成像软件公司)的总裁兼首席执行官(从2008年到2012年)。他最初于2005年1月加入Vital Images,担任首席运营官和首席财务官。在Vital Images 任职期间,他领导公司成为保健和医疗软件行业的领导者。在他的领导下,公司的收入和利润增长,全球市场份额增加,遍布90多个国家,并股权融资筹集了1亿美元。此前,他担任Zamba集团(上市科技公司)的总裁兼首席执行官,以及NextNet Wireless(即插即用宽带无线接入系统的私人供应商,现在属于摩托罗拉公司)的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。
Michael H. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
Robert S. White

Robert S. White,他曾一直担任我们的董事(2013年3月以来)。他目前担任TYRX(一家私人公司,最近被Medtronic收购,TYRX 商业化创新、植入式药物组合和设备产品集中在感染控制,包括AIGISRx抗菌信封,旨在用心脏植入电子设备减少手术部位感染)的总裁兼首席执行官。加入TYRX之前,他担任美敦力公司多个职位。在39亿美元收购脊柱治疗业务之后,他担任Medtronic Kyphon的总裁。任职美敦力公司期间,他还担任的总裁,负责理疗专家控制,以及美国全球销售和营销的副总裁,负责心脏节律疾病管理业务的商业运作。在他的职业生涯中,他任职通用电气公司和礼来公司。他持有密苏里大学的航空航天工程学士学位,以及康奈尔大学工商管理学硕士学位。董事会相信,他的重要医疗设备行业的知识和成长型企业的任职经验,对AtriCure有独特的好处,并能够提高其业务发展计划的能力。


Robert S. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018 a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.
Robert S. White,他曾一直担任我们的董事(2013年3月以来)。他目前担任TYRX(一家私人公司,最近被Medtronic收购,TYRX 商业化创新、植入式药物组合和设备产品集中在感染控制,包括AIGISRx抗菌信封,旨在用心脏植入电子设备减少手术部位感染)的总裁兼首席执行官。加入TYRX之前,他担任美敦力公司多个职位。在39亿美元收购脊柱治疗业务之后,他担任Medtronic Kyphon的总裁。任职美敦力公司期间,他还担任的总裁,负责理疗专家控制,以及美国全球销售和营销的副总裁,负责心脏节律疾病管理业务的商业运作。在他的职业生涯中,他任职通用电气公司和礼来公司。他持有密苏里大学的航空航天工程学士学位,以及康奈尔大学工商管理学硕士学位。董事会相信,他的重要医疗设备行业的知识和成长型企业的任职经验,对AtriCure有独特的好处,并能够提高其业务发展计划的能力。
Robert S. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018 a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.
Daniel P. Florin

Daniel P. Florin于2018年2月被任命为执行副总裁兼首席财务官。在此任命之前,他于2015年6月至2018年2月担任高级副总裁兼首席财务官。此外,他还担任过临时首席执行官。 2017年7月至2017年12月。在Biomet合并之前,Florin先生于2007年6月至2015年6月担任Biomet的高级副总裁兼首席财务官。在加入Biomet之前,他曾担任波士顿科学公司的副总裁兼公司财务总监。 2001年至2007年5月。在此之前,Florin先生曾在Boston Scientific Corporation及其各个业务部门担任财务领导职位。 在加入波士顿科学公司之前,Florin先生于1990年10月至1995年6月在C.R.Bard工作。


Daniel P. Florin has served as one of our directors since December 2019. Mr. Florin most recently served as Executive Vice President at Zimmer Biomet Holdings, a publicly-held global leader in musculoskeletal healthcare until March 2020. He was appointed to his position in July 2019 upon announcing his intention to retire from the company. Previously he served as Executive Vice President and Chief Financial Officer of the company from June 2015 to July 2019. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet, Mr. Florin was Chief Financial Officer for Biomet, Inc. until the company merged with Zimmer, Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP. Mr. Florin has served on the Board of Directors of Pulmonx since January 2020. Mr. Florin received an undergraduate degree from the University of Notre Dame and earned his M.B.A. from Boston University Executive MBA program.
Daniel P. Florin于2018年2月被任命为执行副总裁兼首席财务官。在此任命之前,他于2015年6月至2018年2月担任高级副总裁兼首席财务官。此外,他还担任过临时首席执行官。 2017年7月至2017年12月。在Biomet合并之前,Florin先生于2007年6月至2015年6月担任Biomet的高级副总裁兼首席财务官。在加入Biomet之前,他曾担任波士顿科学公司的副总裁兼公司财务总监。 2001年至2007年5月。在此之前,Florin先生曾在Boston Scientific Corporation及其各个业务部门担任财务领导职位。 在加入波士顿科学公司之前,Florin先生于1990年10月至1995年6月在C.R.Bard工作。
Daniel P. Florin has served as one of our directors since December 2019. Mr. Florin most recently served as Executive Vice President at Zimmer Biomet Holdings, a publicly-held global leader in musculoskeletal healthcare until March 2020. He was appointed to his position in July 2019 upon announcing his intention to retire from the company. Previously he served as Executive Vice President and Chief Financial Officer of the company from June 2015 to July 2019. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet, Mr. Florin was Chief Financial Officer for Biomet, Inc. until the company merged with Zimmer, Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP. Mr. Florin has served on the Board of Directors of Pulmonx since January 2020. Mr. Florin received an undergraduate degree from the University of Notre Dame and earned his M.B.A. from Boston University Executive MBA program.
Scott W. Drake

Scott W. Drake, 2013年9月以来,他担任我们的董事。他目前担任Spectranetics公司的总裁兼首席执行官。Spectranetics是上市公司,从事用于心血管系统的微创手术的医疗器械的发展、生产、市场和销售,其产品远销40多个国家,用于访问和治疗腿、心脏和动脉阻塞,去除起搏器和心脏除颤器。加入Spectranetics从2009年到2011年8月,他担任达维塔公司(一家领先的美国肾脏保健和透析的供应商)的高级副总裁。17年的Covidien任职期间,他在各种医疗业务单位担任多个职位,其责任也越来越大,包括:全球业务单元的总裁,负责呼吸和监控解决方案, 威利(Valleylab)公司(更名为Surgical Solutions Group)的总裁,副总裁兼总经理,负责急救护理。他是Just Right Surgical的联合创始人兼董事。他持有俄亥俄州迈阿密大学工商管理学士学位。


Scott W. Drake has served as one of our directors since September 2013 and as the Chairman of the Board since May 2018. Mr. Drake currently serves as the President and Chief Executive Officer of ViewRay, a publicly-held medical device company with global operations in radiation therapy and imaging technologies. Previously, Mr. Drake was the President, Chief Executive Officer, and member of the Board of Directors of The Spectranetics Corporation from 2011 to 2017. Spectranetics, acquired by Royal Philips in August of 2017 was a publicly-held medical device company that developed, manufactured and distributed single-use medical devices used in minimally invasive procedures within the cardiovascular system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice President, Operations, of DaVita, Inc., a leading U.S. provider of kidney care and dialysis. Previously, Mr. Drake spent 17 years in several leadership positions within numerous healthcare business units at Covidien. From 2006 to 2009 he was President of Covidien’s Respiratory and Monitoring Solutions Global Business Unit, a $1.5 billion business with 8000 employees. Mr. Drake has also served on the Board of Directors for The Zayo Group Holdings, Inc. since November 2018. Mr. Drake is Chairperson of the AdvaMed Radiation Therapy Sector and a board member of the Medical Device Manufacturers Association MDMA. Mr. Drake earned a B.S. in Business Administration from Miami University of Ohio.
Scott W. Drake, 2013年9月以来,他担任我们的董事。他目前担任Spectranetics公司的总裁兼首席执行官。Spectranetics是上市公司,从事用于心血管系统的微创手术的医疗器械的发展、生产、市场和销售,其产品远销40多个国家,用于访问和治疗腿、心脏和动脉阻塞,去除起搏器和心脏除颤器。加入Spectranetics从2009年到2011年8月,他担任达维塔公司(一家领先的美国肾脏保健和透析的供应商)的高级副总裁。17年的Covidien任职期间,他在各种医疗业务单位担任多个职位,其责任也越来越大,包括:全球业务单元的总裁,负责呼吸和监控解决方案, 威利(Valleylab)公司(更名为Surgical Solutions Group)的总裁,副总裁兼总经理,负责急救护理。他是Just Right Surgical的联合创始人兼董事。他持有俄亥俄州迈阿密大学工商管理学士学位。
Scott W. Drake has served as one of our directors since September 2013 and as the Chairman of the Board since May 2018. Mr. Drake currently serves as the President and Chief Executive Officer of ViewRay, a publicly-held medical device company with global operations in radiation therapy and imaging technologies. Previously, Mr. Drake was the President, Chief Executive Officer, and member of the Board of Directors of The Spectranetics Corporation from 2011 to 2017. Spectranetics, acquired by Royal Philips in August of 2017 was a publicly-held medical device company that developed, manufactured and distributed single-use medical devices used in minimally invasive procedures within the cardiovascular system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice President, Operations, of DaVita, Inc., a leading U.S. provider of kidney care and dialysis. Previously, Mr. Drake spent 17 years in several leadership positions within numerous healthcare business units at Covidien. From 2006 to 2009 he was President of Covidien’s Respiratory and Monitoring Solutions Global Business Unit, a $1.5 billion business with 8000 employees. Mr. Drake has also served on the Board of Directors for The Zayo Group Holdings, Inc. since November 2018. Mr. Drake is Chairperson of the AdvaMed Radiation Therapy Sector and a board member of the Medical Device Manufacturers Association MDMA. Mr. Drake earned a B.S. in Business Administration from Miami University of Ohio.

高管简历

中英对照 |  中文 |  英文
Justin J. Noznesky

Justin J. Noznesky,自2016年3月起担任营销及业务开发高级副总裁;此前自2014年5月起担任营销及业务开发副总裁;2014年1月至5月间担任企业开发副总裁;2004年至2013年间担任Vital Images, Inc.(Toshiba Medical Systems Corporation的子公司)的多个金融和业务开发职位,级别渐升,包括营销及业务开发副总裁等。在进入Vital Images之前,他于2002年至2004年间供职于UnitedHealth Group的企业金融方面职务,以及Arthur Andersen的高级审计师一职。他获得了Bethel University的学士学位。


Justin J. Noznesky has served as our Senior Vice President, Marketing and Business Development since March 2016 having previously served as our Vice President, Marketing and Business Development since May 2014 and as our Vice President, Corporate Development from January 2014 to May 2014. From 2004 to 2013 Mr. Noznesky held progressive financial and business development positions at Vital Images, a subsidiary of Toshiba Medical Systems Corporation, including Vice President, Marketing and Business Development. Prior to working for Vital Images, Mr. Noznesky worked at UnitedHealth Group in Corporate Finance and at Arthur Andersen LLP as a senior auditor. Mr. Noznesky received his B.A. from Bethel University.
Justin J. Noznesky,自2016年3月起担任营销及业务开发高级副总裁;此前自2014年5月起担任营销及业务开发副总裁;2014年1月至5月间担任企业开发副总裁;2004年至2013年间担任Vital Images, Inc.(Toshiba Medical Systems Corporation的子公司)的多个金融和业务开发职位,级别渐升,包括营销及业务开发副总裁等。在进入Vital Images之前,他于2002年至2004年间供职于UnitedHealth Group的企业金融方面职务,以及Arthur Andersen的高级审计师一职。他获得了Bethel University的学士学位。
Justin J. Noznesky has served as our Senior Vice President, Marketing and Business Development since March 2016 having previously served as our Vice President, Marketing and Business Development since May 2014 and as our Vice President, Corporate Development from January 2014 to May 2014. From 2004 to 2013 Mr. Noznesky held progressive financial and business development positions at Vital Images, a subsidiary of Toshiba Medical Systems Corporation, including Vice President, Marketing and Business Development. Prior to working for Vital Images, Mr. Noznesky worked at UnitedHealth Group in Corporate Finance and at Arthur Andersen LLP as a senior auditor. Mr. Noznesky received his B.A. from Bethel University.
Salvatore Privitera

Salvatore Privitera先生自2009年5月以来一直担任国我公司工程和产品开发的副总裁。此前的2007年10月至2009年5月的期间,他曾担任业务发展和研究的副总裁。2003年10月至2007年以及2000年和2001年期间,他曾担任公司产品开发的副总裁。Privitera先生曾任Ethicon Endo-Surgery产品开发总监,该公司是一家微创手术器械的开发商和生产厂家。 Privitera先生有20年的医疗产品开发经验,并参与项心脏外科手术、腹腔镜手术、乳腺活检和镇静方面的50多医疗设备的的发布。他是一名有名的发明家,他的35项发明发行并获得了美国专利。Privitera先生是辛辛那提大学(University of Cincinnati)的一名客座教授在。他获得了布法罗大学(University of Buffalo)的学士学位,以及子泽维尔大学(Xavier University)的工商管理硕士学位。目前,他正在攻读大通法学院(Chase College of Law)的法学博士学位。


Salvatore Privitera has served as our Chief Technical Officer since January 2020 having previously served as our Chief Technology Officer since July 2017. Prior to joining AtriCure, Mr. Privitera served as Vice President of Research and Development at Bard Medical "BMD", a division of C.R. Bard, where he helped grow BMD to over $1 billion in global revenue. He was responsible for a broad range of clinical platforms including Therapeutic Hypothermia, Urologic Drainage, Endourology, Brachytherapy, and Home Care where they impacted over 150 million patients on an annual basis. Prior to his role at BMD, Mr. Privitera worked for AtriCure as the Vice President of Engineering and Product Development for nine years. During his tenure at AtriCure, the company grew from a small startup into a public company, and he led development of many platform technologies including the AtriClip product line and the PMA approved Isolator Synergy Ablation System. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles for over twelve years. Mr. Privitera received his B.S. from the University of Buffalo, his M.B.A. from Xavier University and his J.D. from Northern Kentucky University.
Salvatore Privitera先生自2009年5月以来一直担任国我公司工程和产品开发的副总裁。此前的2007年10月至2009年5月的期间,他曾担任业务发展和研究的副总裁。2003年10月至2007年以及2000年和2001年期间,他曾担任公司产品开发的副总裁。Privitera先生曾任Ethicon Endo-Surgery产品开发总监,该公司是一家微创手术器械的开发商和生产厂家。 Privitera先生有20年的医疗产品开发经验,并参与项心脏外科手术、腹腔镜手术、乳腺活检和镇静方面的50多医疗设备的的发布。他是一名有名的发明家,他的35项发明发行并获得了美国专利。Privitera先生是辛辛那提大学(University of Cincinnati)的一名客座教授在。他获得了布法罗大学(University of Buffalo)的学士学位,以及子泽维尔大学(Xavier University)的工商管理硕士学位。目前,他正在攻读大通法学院(Chase College of Law)的法学博士学位。
Salvatore Privitera has served as our Chief Technical Officer since January 2020 having previously served as our Chief Technology Officer since July 2017. Prior to joining AtriCure, Mr. Privitera served as Vice President of Research and Development at Bard Medical "BMD", a division of C.R. Bard, where he helped grow BMD to over $1 billion in global revenue. He was responsible for a broad range of clinical platforms including Therapeutic Hypothermia, Urologic Drainage, Endourology, Brachytherapy, and Home Care where they impacted over 150 million patients on an annual basis. Prior to his role at BMD, Mr. Privitera worked for AtriCure as the Vice President of Engineering and Product Development for nine years. During his tenure at AtriCure, the company grew from a small startup into a public company, and he led development of many platform technologies including the AtriClip product line and the PMA approved Isolator Synergy Ablation System. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles for over twelve years. Mr. Privitera received his B.S. from the University of Buffalo, his M.B.A. from Xavier University and his J.D. from Northern Kentucky University.
Michael H. Carrel

Michael H. Carrel,他担任主席,首席执行官和董事(2012年11月以来)。他担任Vital Images(上市医疗成像软件公司)的总裁兼首席执行官(从2008年到2012年)。他最初于2005年1月加入Vital Images,担任首席运营官和首席财务官。在Vital Images 任职期间,他领导公司成为保健和医疗软件行业的领导者。在他的领导下,公司的收入和利润增长,全球市场份额增加,遍布90多个国家,并股权融资筹集了1亿美元。此前,他担任Zamba集团(上市科技公司)的总裁兼首席执行官,以及NextNet Wireless(即插即用宽带无线接入系统的私人供应商,现在属于摩托罗拉公司)的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。


Michael H. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
Michael H. Carrel,他担任主席,首席执行官和董事(2012年11月以来)。他担任Vital Images(上市医疗成像软件公司)的总裁兼首席执行官(从2008年到2012年)。他最初于2005年1月加入Vital Images,担任首席运营官和首席财务官。在Vital Images 任职期间,他领导公司成为保健和医疗软件行业的领导者。在他的领导下,公司的收入和利润增长,全球市场份额增加,遍布90多个国家,并股权融资筹集了1亿美元。此前,他担任Zamba集团(上市科技公司)的总裁兼首席执行官,以及NextNet Wireless(即插即用宽带无线接入系统的私人供应商,现在属于摩托罗拉公司)的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。
Michael H. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
M. Andrew Wade

M. Andrew Wade, 他是注册会计师。他担任我们的副总裁和首席财务官(2013年1月以来)。他曾担任各种财务职务(自2007年10月加入AtriCure以来),包括财务计划与分析经理、财务总监。加入AtriCure之前,他担任了各种财务职务Macy公司和Saks 公司 。他的职业生涯始于安达信会计师事务所,并在审计实践中,为各行业客户提供服务。他获得了泽维尔大学的会计学士学位,以及范德比尔特大学欧文学院的硕士学位。他是注册会计师。


M. Andrew Wade has served as our Chief Financial Officer since January 2013. From 2007 to 2013 Mr. Wade worked in various financial positions at AtriCure including Manager of Financial Planning & Analysis and Director of Finance. Prior to joining AtriCure, Mr. Wade held various financial positions with Macy’s Inc. and Saks Inc. Mr. Wade started his career with Arthur Andersen LLP in the audit practice, serving clients in various industries. Mr. Wade serves on the Board of Directors of the Cincinnati Chapter of the American Heart Association and previously served on the Board of the Mason, Ohio Port Authority from 2015 to July of 2019. Mr. Wade received his B.S.B.A. in Accounting from Xavier University and his M.B.A from the Owen School at Vanderbilt University and is a Certified Public Accountant.
M. Andrew Wade, 他是注册会计师。他担任我们的副总裁和首席财务官(2013年1月以来)。他曾担任各种财务职务(自2007年10月加入AtriCure以来),包括财务计划与分析经理、财务总监。加入AtriCure之前,他担任了各种财务职务Macy公司和Saks 公司 。他的职业生涯始于安达信会计师事务所,并在审计实践中,为各行业客户提供服务。他获得了泽维尔大学的会计学士学位,以及范德比尔特大学欧文学院的硕士学位。他是注册会计师。
M. Andrew Wade has served as our Chief Financial Officer since January 2013. From 2007 to 2013 Mr. Wade worked in various financial positions at AtriCure including Manager of Financial Planning & Analysis and Director of Finance. Prior to joining AtriCure, Mr. Wade held various financial positions with Macy’s Inc. and Saks Inc. Mr. Wade started his career with Arthur Andersen LLP in the audit practice, serving clients in various industries. Mr. Wade serves on the Board of Directors of the Cincinnati Chapter of the American Heart Association and previously served on the Board of the Mason, Ohio Port Authority from 2015 to July of 2019. Mr. Wade received his B.S.B.A. in Accounting from Xavier University and his M.B.A from the Owen School at Vanderbilt University and is a Certified Public Accountant.
Douglas J. Seith

Douglas J. Seith自2013年1月起在本公司担任高级副总裁职务,服务于销售和市场营销等领域。 从2011年4月在本公司担任副总裁,负责美国区域的销售工作。 从2004年加入AtriCure公司作为区域销售负责人。Seith先生曾经负责过各种销售的领导职位,包括:区域总监。 他拥有超过25年的心脏和普通外科领域的销售和领导经验。在加入AtriCure之前,他在A-Med/EmoblX公司担任销售/领导的职位。 他担任过很多公司的销售副总裁职务,如:Heartport, Scimed Life Systems, a division of Boston Scientific, Automated Instruments a division of Unites States Surgical Corporation。 他在俄亥俄卫斯理大学取得了文科学士学位。


Douglas J. Seith has served as our Chief Operating Officer since January 2015 having previously served as our Senior Vice President, Sales and Marketing from 2013 to 2014 and as our Vice President, United States Sales from 2011 to 2013. Since joining AtriCure in 2004 as a Regional Sales Leader, Mr. Seith has held a variety of progressive sales and sales leadership positions, including Area Director roles. Mr. Seith has over 25 years of cardiology and general surgery sales and sales leadership experience. Prior to joining AtriCure, Mr. Seith held sales leadership and/or sales positions with A-Med/EmoblX, Inc., where he was the Vice President of Sales, Heartport, Inc., Scimed Life Systems, a division of Boston Scientific, Inc. and Automated Instruments a division of Unites States Surgical Corporation. Mr. Seith received his B.A. from Ohio Wesleyan University.
Douglas J. Seith自2013年1月起在本公司担任高级副总裁职务,服务于销售和市场营销等领域。 从2011年4月在本公司担任副总裁,负责美国区域的销售工作。 从2004年加入AtriCure公司作为区域销售负责人。Seith先生曾经负责过各种销售的领导职位,包括:区域总监。 他拥有超过25年的心脏和普通外科领域的销售和领导经验。在加入AtriCure之前,他在A-Med/EmoblX公司担任销售/领导的职位。 他担任过很多公司的销售副总裁职务,如:Heartport, Scimed Life Systems, a division of Boston Scientific, Automated Instruments a division of Unites States Surgical Corporation。 他在俄亥俄卫斯理大学取得了文科学士学位。
Douglas J. Seith has served as our Chief Operating Officer since January 2015 having previously served as our Senior Vice President, Sales and Marketing from 2013 to 2014 and as our Vice President, United States Sales from 2011 to 2013. Since joining AtriCure in 2004 as a Regional Sales Leader, Mr. Seith has held a variety of progressive sales and sales leadership positions, including Area Director roles. Mr. Seith has over 25 years of cardiology and general surgery sales and sales leadership experience. Prior to joining AtriCure, Mr. Seith held sales leadership and/or sales positions with A-Med/EmoblX, Inc., where he was the Vice President of Sales, Heartport, Inc., Scimed Life Systems, a division of Boston Scientific, Inc. and Automated Instruments a division of Unites States Surgical Corporation. Mr. Seith received his B.A. from Ohio Wesleyan University.